Zura Bio to Participate in Cantor Global Healthcare Conference
Zura Bio announced that members of its management team will participate in an upcoming investor conference, including a fireside chat and one-on-one investor meetings. A live webcast will be available with a replay accessible for at least 30 days. The company highlighted ongoing Phase 2 studies for tibulizumab and planned initiation of a Phase 2 study for polymyalgia rheumatica by year-end 2026.